The Technical Analyst
Select Language :
Monopar Therapeutics Inc [MNPR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Monopar Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Monopar Therapeutics Inc is listed at the  Exchange

-7.60% $0.681

America/New_York / 28 mar 2024 @ 16:00


Monopar Therapeutics Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 10.12 mill
EPS: -0.720
P/E: -0.950
Earnings Date: Mar 27, 2024
SharesOutstanding: 14.87 mill
Avg Daily Volume: 5.56 mill
RATING 2024-03-28
B-
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Sell
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debtn/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.950 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.16x
Company: PE -0.950 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.526
(-22.82%) $-0.155
Date: 2024-03-29
Expected Trading Range (DAY)

$ 0.462 - 0.900

( +/- 32.16%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-12-31 Anderson Raymond Buy 2 533 Common Stock
2023-12-31 Anderson Raymond Sell 2 533 Restricted Stock Units
2023-12-31 Brown Michael J Buy 2 533 Common Stock
2023-12-31 Brown Michael J Sell 2 533 Restricted Stock Units
2023-12-31 Cittadine Andrew Sell 8 952 Restricted Stock Units
INSIDER POWER
44.77
Last 100 transactions
Buy: 1 096 465 | Sell: 297 348

Forecast: 16:00 - $0.692

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $0.692
Forecast 2: 16:00 - $0.692
Forecast 3: 16:00 - $0.692
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.681 (-7.60% )
Volume 0.288 mill
Avg. Vol. 5.56 mill
% of Avg. Vol 5.18 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Monopar Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Monopar Therapeutics Inc

RSI

Intraday RSI14 chart for Monopar Therapeutics Inc

Last 10 Buy & Sell Signals For MNPR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Monopar Therapeutics Inc

MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Last 10 Buy Signals

Date Signal @
GTUSDMar 29 - 06:43$9.65
WNXMUSDMar 29 - 06:3872.57
ALPHUSDMar 29 - 06:362.72
LEASHUSDMar 29 - 06:34572.59
FLIPUSDMar 29 - 06:345.05
XMONUSDMar 29 - 06:29911.39
AVTUSDMar 29 - 06:275.77
DIGGUSDMar 29 - 06:24899.52
HTUSDMar 29 - 06:23$0.867
CTXUSDMar 29 - 06:194.96

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.